Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Solid Biosciences Inc.
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Number of employees : 121 people.
Managers and Directors
NameAgeSinceTitle
Ilan Ganot462018President, Chief Executive Officer & Director
Ian Frederick Smith542020Chairman
Jennifer Ziolkowski462017Chief Financial Officer & Treasurer
Carl Morris, Dr.502017Chief Scientific Officer
Joel Schneider, Dr.352017Chief Technology Officer
Cathryn M. Clary, Dr.--Chief Medical Officer
Robert Huffines552013Independent Director
Lynne Sullivan542015Independent Director
Matthew Bennett Arnold512013Independent Director
Adam Stone402015Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 60,449,341 30,106,446 49.8% 0 0.0% 49.8%
Shareholders
NameEquities%
Perceptive Advisors LLC 10,803,857 17.9%
RA Capital Management LP 9,976,469 16.5%
Ultragenyx Pharmaceutical Inc. 7,825,797 12.9%
Bain Capital Life Sciences LP 7,060,353 11.7%
Ecor1 Capital LLC 5,275,000 8.73%
Gilad D. Hayeem 4,441,972 7.35%
Matthew Bennett Arnold 3,933,429 6.51%
Invus Public Equities Advisors LLC 1,710,000 2.83%
Tavistock Life Sciences Co. (Investment Management) 1,531,872 2.53%
Ilan Ganot 1,473,168 2.44%
Company contact information
Solid Biosciences, Inc.
141 Portland Street
5th floor
Cambridge, MA 02139

Phone : +1.617.337.4680
Web : http://www.solidbio.com
Sector Bio Therapeutic Drugs